| Literature DB >> 19674789 |
Walter Fiedler1, Rolf Mesters, Michael Heuser, Gerhard Ehninger, Wolfgang E Berdel, Ute Zirrgiebel, Jane D Robertson, Tom A Puchalski, Barbara Collins, Juliane M Jürgensmeier, Hubert Serve.
Abstract
VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of < or =30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy. Copyright 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19674789 DOI： 10.1016/j.leukres.2009.07.020
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156